<?xml version="1.0" encoding="UTF-8"?>
<p>Povidone-iodine (PVP-I) drops is another potential agent for the treatment of adenoviral conjunctivitis
 <xref rid="B16" ref-type="bibr">
  <sup>16</sup>
 </xref>. Studies investigating PVP-I in combination with topical steroids (0.1% dexamethasone) have shown a reduction in symptoms and viral titre in both humans and rabbit models.
 <xref rid="B17" ref-type="bibr">
  <sup>17</sup>
 </xref>,
 <xref rid="B18" ref-type="bibr">
  <sup>18</sup>
 </xref> A recently published Phase 2 randomised controlled trial suggests some benefit of a combination treatment of PVP-I and dexamethasone in terms of speed of clinical resolution and adenoviral eradication, although this is not yet commercially available and the potential of significant steroid-induced side-effects has not been fully investigated.
 <xref rid="B19" ref-type="bibr">
  <sup>19</sup>
 </xref>,
 <xref rid="B20" ref-type="bibr">
  <sup>20</sup>
 </xref>
</p>
